行情

CNAT

CNAT

Conatus制药
NASDAQ

实时行情|Nasdaq Last Sale

0.4503
+0.0189
+4.38%
已收盘, 17:47 01/21 EST
开盘
0.4300
昨收
0.4314
最高
0.4820
最低
0.4300
成交量
298.18万
成交额
--
52周最高
3.080
52周最低
0.2500
市值
1,493.67万
市盈率(TTM)
-1.1651
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CNAT 新闻

  • 谷歌CEO皮查伊:隐私是我们工作的核心
  • 新浪科技.2小时前
  • 谷歌CEO:AI或许是目前最重要的发明 比电的意义更大
  • 新浪科技.2小时前
  • 特朗普达沃斯演讲:种一万亿棵树,我们加入
  • 新浪财经-自媒体综合.2小时前
  • 霍尼韦尔:竭尽全力保障KN95口罩在春节期间持续供应
  • 澎湃新闻.3小时前

更多

所属板块

生物技术和医学研究
-0.61%
制药与医学研究
-0.39%

热门股票

名称
价格
涨跌幅

CNAT 简况

Conatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease. Emricasan has the potential to interrupt the progression of liver disease and provide treatment options in multiple areas of liver disease. Emricasan is designed to slow or halt the progression of chronic liver disease caused by fibrosis and cirrhosis. Emricasan works by inhibiting caspases, which are a family of related enzymes that plays as modulators of critical cellular functions, including functions that result in apoptosis and inflammation.
展开

Webull提供Conatus Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。